Delusional. Dr. Liau did an interim analysis that the PFS data looked like it was failing. Then 2 WEEKS before the FINAL trial Data Lock, NWBO announced a complete change in the protocol, endpoints, comparator and even added the R/R GBM arm. Unbelievable but true. They didn't have any FDA vetting of the changes, they just did it because they knew they were blowing the primary endpoint. FDA told them don't bother filing an application or they clearly would have.
Even Dr. Liau knows that DCVax-L isn't enough by itself -- she designed the SPORE study with multiple additional agents.
"Many of the BP products have multiple negative outcomes" -- False -- please show evidence of MANY BP Products with MULTIPLE negative outcomes. B.S.
What NWBO progress?? MHRA is clearly in no hurry to approve DCVax-L or they would have. 150 day review and it is now 18 month. Even the investment community isn't buying it as the share price has been steadily dropping and now 40%. Even NWBO knows they are in trouble as they haven't made ANY attempt to build a commercial capability. Sorry, it's not looking good. NICE won't pay for it even if it was approved. It took over 5 years for a proven oncology treatment like CAR-T to get any NICE support and that was only the NICE charity covering only 100 patients a year.
Your claim as to why Oncologists use SOC is because that is the only treatments that payers will PAY FOR!!! Oncologists know it they want to try experimental treatments or protocols that it won't get paid for. Keep up the conspiracy theory. It's the payers that control the money.
Market Data 
Markets 
